MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Shire PLC Company Profile (LON:SHP)

Consensus Ratings for Shire PLC (LON:SHP) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 16 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: GBX 5,771.33

Analysts' Ratings History for Shire PLC (LON:SHP)
Show:
DateFirmActionRatingPrice TargetActions
6/15/2016BNP ParibasReiterated RatingOutperformGBX 5,700View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016RBC CapitalReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Shore CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Deutsche BankReiterated RatingBuyGBX 5,600View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Jefferies GroupBoost Price TargetBuyGBX 5,150 -> GBX 6,050View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016Morgan StanleyReiterated RatingOverweightGBX 5,600View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016JPMorgan Chase & Co.Reiterated RatingOverweightGBX 5,600View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Credit SuisseReiterated RatingOutperformGBX 5,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016HSBCReiterated RatingBuyGBX 5,400View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Sanford C. BernsteinReiterated RatingOutperformGBX 5,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016AlphaValueReiterated RatingBuyGBX 6,420View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/17/2016Berenberg BankLower Price TargetBuyGBX 6,300 -> GBX 5,400View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/5/2016BarclaysReiterated RatingOverweightGBX 5,700View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015InvestecDowngradeSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2015Kepler Capital MarketsLower Price TargetBuyGBX 6,000 -> GBX 5,900View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/19/2015Bank of AmericaReiterated RatingNeutralGBX 6,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/4/2015Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015Goldman SachsReiterated RatingConviction-BuyGBX 6,800View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2015XYZ ResearchReiterated RatingOutperformGBX 6,600View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2015Charles StanleyReiterated RatingaccumulateView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Shire PLC (LON:SHP)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Shire PLC (LON:SHP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Shire PLC (LON:SHP)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/11/2016GBX 15.320.44%3/10/20163/10/20164/12/2016Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015GBX 2.690.05%9/3/20159/3/201510/2/2015Tweet This Announcement  Share This Announcement on StockTwits
7/18/2014GBX 2.240.04%9/3/20149/3/201410/3/2014Tweet This Announcement  Share This Announcement on StockTwits
2/13/2014GBX 10.210.31%3/5/20143/5/20144/8/2014Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Shire PLC (LON:SHP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/31/2016Bohuon,OlivierInsiderBuy133GBX 3,908£5,197.64Tweet This Trade  Share This Trade on StockTwits
2/15/2016Bohuon,OlivierInsiderBuy1,000GBX 3,552£35,520Tweet This Trade  Share This Trade on StockTwits
2/12/2016Burns,WilliamInsiderBuy1,250GBX 3,563£44,537.50Tweet This Trade  Share This Trade on StockTwits
12/18/2015Burns,WilliamInsiderBuy156GBX 4,457£6,952.92Tweet This Trade  Share This Trade on StockTwits
9/30/2015Blakemore ,DominicInsiderBuy129GBX 4,498£5,802.42Tweet This Trade  Share This Trade on StockTwits
6/30/2015Kappler,David JInsiderBuy126GBX 51.05GBX 6,432.30Tweet This Trade  Share This Trade on StockTwits
3/31/2015Susan KilsbyInsiderBuy375GBX 5,327£19,976.25Tweet This Trade  Share This Trade on StockTwits
12/19/2014Steven GillisInsiderBuy228GBX 4,654£10,611.12Tweet This Trade  Share This Trade on StockTwits
10/30/2014Steven GillisInsiderBuy381GBX 4,098£15,613.38Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Shire PLC (LON:SHP)
DateHeadline
06/18/16 05:31 PMDeutsche Bank disclosed (LON:SHP) Shire PLC, keeping its stock price target to GBX5,600 today - Breaking Finance News
06/18/16 10:27 AMDeutsche Bank disclosed (LON:SHP) Shire PLC, keeping its stock price target to GBX5,600 today
06/16/16 06:36 PMRBC Capital Markets reported on (LON:SHP) Shire PLC, maintaining its target price to GBX0 earlier today
06/16/16 10:47 AMRBC Capital Markets reported on (LON:SHP) Shire PLC, maintaining its target price to GBX0 earlier today - Breaking Finance News
06/15/16 10:52 AMShire, Kamada: FDA Approves Expanded Label For Self-infusion Of GLASSIA
06/14/16 11:09 AMSHIRE PLC : - Additional Listing
06/14/16 11:09 AMShire To License IBD Drug PF-00547659 From Pfizer; Terms Not Disclosed
06/14/16 11:09 AMCompany Update (NYSE:PFE): Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio
06/13/16 09:21 AMShire : Gets Breakthrough Therapy Designation For SHP621 And SHP625
06/13/16 09:21 AMShire Gets FDA Breakthrough Therapy Designation For 2 Products For Rare Diseases
06/13/16 09:21 AMShire Receives FDA Breakthrough Therapy Designation for SHP621 and SHP625, Investigational Products for Rare Gastrointestinal Conditions
06/10/16 09:23 AMJefferies International Reiterated Shire PLC (LON:SHP) As 'Buy' - FTSE News
06/09/16 12:30 PMETF’s with exposure to Shire Plc : June 9, 2016 -
06/09/16 05:19 AM9 Jun 2016 Shire and Oriola extend their cooperation in Finland - [at noodls] - Shire and Oriola have signed an agreement to extend their cooperation in Finland. Oriola offers Shire pharmaceutical storage and distribution services and a broad range of tailored services both in Finland ...
06/08/16 09:27 AMSHIRE PLC - Directorate Change
06/06/16 02:40 AMAre Aviva plc (-15%), Prudential plc (-16%) and Shire plc (-25%) set to make a fighting comeback? -
06/05/16 09:05 AMShire PLC (SHP) Stock Rating Reaffirmed by Credit Suisse - Let Me Know About This
06/04/16 06:29 PMShire PLC (SHP) Rating Reiterated by JPMorgan Chase & Co. - Let Me Know About This
06/04/16 09:21 AMShire Completes Combination With Baxalta - Quick Facts - Nasdaq
06/03/16 07:01 PMMorgan Stanley Reiterates Overweight Rating for Shire PLC (SHP) - Let Me Know About This
06/03/16 04:32 PMShire Closes Baxalta Buyout, Sparking Higher Growth Forecast -
06/03/16 07:15 AMShire to participate at two upcoming ... - [at noodls] - June 3, 2016 Lexington, MA, USA - June 3, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will present at the Goldman Sachs 37th Annual Global Healthcare ...
06/03/16 07:10 AMShire completes Baxalta acquisition, creating state's biggest pharma company -
06/03/16 07:00 AMShire to Participate at Two Upcoming Investor Conferences - [PR Newswire] - LEXINGTON, Massachusetts, June 3, 2016 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will present at the Goldman Sachs 37th Annual Global Healthcare ...
06/03/16 02:55 AMShire completes combination with ... - [at noodls] - June 3, 2016 Combined company expected to deliver double-digit compound annual top-line growth with over $20 billion in annual revenues by 2020 Rare disease portfolio expected to immediately generate approximately ...
06/03/16 02:45 AMAcquisition - Shire Completes Combination With Baxalta - [at noodls] - Acquisition - Shire Completes Combination With Baxalta The text version of this document is not available at the moment. The original content was posted at original link . Shire plc published this content ...
06/03/16 02:40 AMShire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions - [PR Newswire] - Shire plc (LSE: SHP, NASDAQ: SHPG) today completed its previously announced combination with Baxalta Incorporated (BXLT), creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. Through the combination, Shire expects to deliver double-digit compound annual top-line growth, with over $20 billion in annual projected revenue by 2020 and approximately 65% of total annual revenues being immediately generated by its rare disease products. Shire now has more than 50 programs in clinical development, with a balanced mix of early, mid and late-stage projects.
06/02/16 09:32 AMSHIRE PLC - Additional Listing - June 1, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that, following the General Meeting of the Company and the meeting of Baxalta Incorporated’s (“Baxalta”) shareholders on May 27, 2016, approving the Merger, Completion of ...
06/01/16 07:01 PMDeutsche Bank Indicated Shire PLC (LON:SHP) As 'Buy' - FTSE News - Deutsche Bank Indicated Shire PLC (LON:SHP) As 'Buy'FTSE NewsDeutsche Bank Indicated Shire PLC (LON:SHP) As 'Buy'. By Warren Smith / in UK Broker Ratings / on Wednesday, 01 Jun 2016 09:00 AM / 0 Comments. On Tuesday analysts at Deutsche Bank indicated Shire PLC's (LON:SHP) shares as 'Buy' in a research ...and more »
06/01/16 09:21 AMShire PLC's (SHP) Buy Rating Reaffirmed at Deutsche Bank - Let Me Know About This - Risers & FallersShire PLC's (SHP) Buy Rating Reaffirmed at Deutsche BankLet Me Know About ThisShire PLC logo Shire PLC (LON:SHP)'s stock had its “buy” rating reaffirmed by research analysts at Deutsche Bank in a research note issued to investors on Tuesday. They presently have a GBX 5,600 ($81.97) price target on the biopharmaceutical ...Shire PLC (LON:SHP) Receives Outperform Rating From Credit Suisse AnalystsRisers & FallersShire PLC (LON:SHP) Receives 'Overweight' Rating From JP MorganShare Trading NewsDeutsche Bank Indicated Shire PLC (LON:SHP) As 'Buy'FTSE NewsHNN -DirectorsTalk Interviews -Proactive Investors UKall 401 news articles »
05/31/16 09:47 AMShire PLC (SHP) Rating Reiterated by Deutsche Bank - Let Me Know About This - Share Trading NewsShire PLC (SHP) Rating Reiterated by Deutsche BankLet Me Know About ThisShire PLC logo Shire PLC (LON:SHP)'s stock had its “buy” rating reaffirmed by Deutsche Bank in a research report issued on Tuesday. They currently have a GBX 5,600 ($81.97) price target on the biopharmaceutical company's stock. Deutsche Bank's price ...Shire PLC (LON:SHP) Receives 'Buy' Rating From Deutsche BankShare Trading NewsHow Many Shire PLC (LON:SHP)'s Analysts Are Bullish?HNNShire PLC 30.2% Potential Upside Indicated by Deutsche BankDirectorsTalk InterviewsRisers & Fallersall 611 news articles »
05/28/16 08:42 PMHow Many Shire PLC (LON:SHP)'s Analysts Are Bullish? - HNN - How Many Shire PLC (LON:SHP)'s Analysts Are Bullish?HNNOut of 14 analysts covering Shire PLC (LON:SHP), 16 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 94% are positive. Shire PLC has been the topic of 144 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Below is a list of ...and more »
05/28/16 02:33 AMBaxalta Shareholders Vote to Approve Combination - at a special meeting of shareholders held earlier this morning relating to the proposed combination with Shire plc (LSE: SHP, NASDAQ: SHPG). Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the ...
05/28/16 02:33 AMShire shareholders approve $32 bln Baxalta merger - LONDON--Shareholders of Dublin-based pharmaceutical company Shire PLC SHP Friday approved the company's proposed $32 billion merger with Bannockburn, Ill-based Baxalta Incorporated BXLT, -0.02% at the general meeting, and the deal is expected to close on ...
05/27/16 05:15 AMShire shareholders approve Baxalta merger -
05/20/16 10:27 AMSpecialty Pharma Stocks are Cheap…But Only Some are Worth Buying -
05/19/16 10:34 AMOutstanding Analyst Ratings For Shire Plc (LON:SHP) - FTSE News - Outstanding Analyst Ratings For Shire Plc (LON:SHP)FTSE NewsNumerous investment brokers have in recent days changed their price targets on shares of Shire Plc (LON:SHP). According to data retrieved from Reuters, on Thursday 19th of May, 21 analyst has a rating of “strong buy”, 1 analysts “buy”, 3 analysts ...and more »
05/19/16 05:00 AMDon’t ignore 10 years running of increased dividends at BAE Systems plc, Prudential plc and Shire plc -
05/13/16 04:03 AMAre Sky plc, Shire plc and Taylor Wimpey plc the perfect growth plays? - Shire (LSE: SHP) is an emerging pharma giant that’s far less well known than its peers AstraZeneca and GlaxoSmithKline, yet this is a company that’s worth £24bn. It specialises in producing a broad range of treatments for rare diseases and is ...
05/12/16 10:17 AMShire Hotels shortlisted in industry awards - [at noodls] - Kettering Park Hotel & Spa and Thorpe Park Hotel & Spa have been named among the best venues in the country. They have been shortlisted in the CHS Awards 16 - industry awards recognising different aspects ...
05/12/16 05:16 AMShire launches awareness campaign to improve lives of people with rare MPS - Shire plc (LSE: SHP, NASDAQ: SHPG) announces a campaign to enable people to connect and share information about MPS (mucopolysaccharide) diseases around the world. MPS is a group of genetic diseases and is one of approximately 7,000 rare diseases worldwide ...
05/09/16 09:41 PMShire Plc (LON:SHP) Broker Price Targets - Share Trading News - Shire Plc (LON:SHP) Broker Price TargetsShare Trading NewsRecently stock market research analysts have changed their consensus ratings and price targets on shares of Shire Plc (LON:SHP). The latest broker reports which are currently outstanding on Monday 9th of May state 21 analyst has a rating of “strong buy ...and more »
05/09/16 02:56 PMETF’s with exposure to Shire Plc : May 9, 2016 -
05/09/16 03:39 AMShire Plc breached its 50 day moving average in a Bearish Manner : SHP-GB : May 9, 2016 -
05/09/16 01:27 AMShire PLC (LON:SHP) Receives GBX 5758 Average PT from Analysts - Washington News Wire - Share Trading NewsShire PLC (LON:SHP) Receives GBX 5758 Average PT from AnalystsWashington News WireShire PLC logo Shares of Shire PLC (LON:SHP) have been assigned a consensus rating of “Buy” from the nineteen ratings firms that are covering the company, Analyst Ratings.Net reports. One research analyst has rated the stock with a sell recommendation, ...Shire Plc (LON:SHP) Broker Price TargetsShare Trading NewsHow Many Shire PLC (LON:SHP)'s Analysts Are Bullish?The Postall 343 news articles »
05/06/16 04:51 AMLiberum initiates Shire at 'buy' despite Baxalta -
05/05/16 06:48 AMDirector dealing: Shire board shell out -
05/05/16 01:37 AMShire Plc (LON:SHP) Receives 'Outperform' Rating From Brokers At Credit Suisse - FTSE News - Shire Plc (LON:SHP) Receives 'Outperform' Rating From Brokers At Credit SuisseFTSE NewsShire Plc (LON:SHP) Receives 'Outperform' Rating From Brokers At Credit Suisse. By Warren Smith / in UK Broker Ratings / on Wednesday, 04 May 2016 04:00 PM / 0 Comments. Shire Plc (LON:SHP) yesterday was the subject of a new research report ...Analysts At Credit Suisse Reiterated Shire Plc (LON:SHP) As OutperformRisers & FallersShire Plc (LON:SHP) reiterated as 'Buy' At JefferiesShare Trading NewsShire PLC (LON:SHP) Receives Average Recommendation of "Buy" from BrokeragesWeb Breaking Newsall 10 news articles »
05/05/16 01:14 AMShire Plc :SHP-GB: Earnings Analysis: Q1, 2016 By the Numbers -
05/03/16 09:25 PMShire Plc (LON:SHP) reiterated as 'Buy' At Jefferies - Share Trading News - Shire Plc (LON:SHP) reiterated as 'Buy' At JefferiesShare Trading NewsShire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, ...Analysts At Credit Suisse Reiterated Shire Plc (LON:SHP) As OutperformRisers & Fallersall 7 news articles »
About Shire PLC

Shire PLC logoShire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company focuses its development resources on projects in various therapeutic areas (TAs), including rare diseases, neuroscience, ophthalmics, hematology and gastrointestinal (GI), and focuses its early development projects primarily on rare diseases. Its products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ, ADDERALL XR, INTUNIV, LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SHP
  • CUSIP:
Key Metrics:
  • Previous Close: $60.29
  • 50 Day Moving Average: $4176.11
  • 200 Day Moving Average: $4104.03
  • P/E Ratio: 18.51
  • P/E Growth: 0.89
  • Market Cap: $24.30B
  • Current Quarter EPS Consensus Estimate: $4.24 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha